Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Atherosclerotic cardiovascular disease (ASCVD) remains a major cause of death, with elevated low-density lipoprotein (LDL) cholesterol as a primary driver.
• Statins are established therapies, but some patients require additional or alternative lipid-lowering strategies.

Approach:

• This review synthesizes current clinical trial data on recently approved nonstatin lipid-lowering agents.
• It examines indications, efficacy, safety, and practical considerations for prescribing these medications.
• A framework is proposed for integrating nonstatin therapy into ASCVD management.

Key Points:

• Several novel nonstatin drugs are now available for LDL cholesterol reduction.
• These agents provide valuable adjunct or alternative options to statin therapy for ASCVD.
• Clinical evidence supports their role in managing high-risk patient populations.

Conclusions:

• Nonstatin therapies represent an important advancement in managing dyslipidemia and reducing ASCVD risk.
• Understanding their evidence base and prescribing nuances is crucial for optimal patient care.
• A systematic approach can help determine appropriate initiation of nonstatin lipid-lowering treatments.